about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Roche writes off ul­cer­a­tive col­i­tis por­tion of etrolizum­ab pro­gram, days af­ter dis­sect­ing PhI­II set­back

5 years ago
R&D

Pa­tient death in piv­otal gene ther­a­py tri­al rat­tles Sarep­ta part­ner al­ready fac­ing clin­i­cal hold

5 years ago
R&D
Cell/Gene Tx

No­var­tis bet $6B on the idea — now Ver­sant, ven­Bio have $45M to birth a plat­form play for ra­dio­phar­ma­ceu­ti­cals

5 years ago
Financing
Startups

News brief­ing: Re­gen­eron/Sanofi post pos­i­tive PhI­II Dupix­ent da­ta in pe­di­atric asth­ma; Vineti scores $33M Se­ries C ...

5 years ago
News Briefing

Months af­ter re­tir­ing from Genen­tech, Michael Var­ney brings his drug hunt­ing eye to Fra­zier

5 years ago
People
Financing

Out to pi­o­neer gene edit­ing in Chi­na, Edi­Gene bags $67M to be­gin clin­i­cal test­ing for β-tha­lassemia ther­a­py, ...

5 years ago
Financing
China

Park­er In­sti­tute sum­moned the neoanti­gen pi­o­neers to com­pare their pre­dic­tion al­go­rithms. And they have some ...

5 years ago
Discovery

It's not just the an­ti­bod­ies: Eli Lil­ly bur­nish­es its sec­ond EUA in play with new Covid-19 da­ta on Olu­mi­ant plus ...

5 years ago
R&D
Coronavirus

How hot is Hong Kong's biotech IPO mar­ket? Two biotechs just raised $800M to­tal

5 years ago
Financing
China

Take­da drops $300M cash to kick off $1B RNAi al­liance with Ar­row­head, shoot­ing for first-in-class rare dis­ease drug

5 years ago
Deals

Covid-19 roundup: Azar says US could have vac­cines for all by March; Mod­er­na gets $56M to build mo­bile vac­cine ...

5 years ago
Coronavirus

'I've au­tho­rized it' — Trump promis­es quick EUA and free ac­cess to Re­gen­eron's an­ti­body cock­tail, call­ing it a ...

5 years ago
Coronavirus

Ven­rock takes the wrap off its first mi­cro­bio­me start­up, armed with $50M, a CEO from 23andMe and two founders from ...

5 years ago
Financing
Startups

Roche joins Ab­b­Vie in step­ping on Ver­tex's turf, bet­ting $96M on an al­ter­na­tive CF ap­proach

5 years ago
Deals

Oc­cu­pied with im­munol­o­gy and can­cer, Mer­ck KGaA hands off os­teoarthri­tis drug to No­var­tis for €50M cash

5 years ago
Deals

No new guid­ance, but here's some ad­vice: FDA draws a line in the sand for Covid-19 vac­cine de­vel­op­ers

5 years ago
FDA+
Coronavirus

GSK, Vir cleared to leap in­to PhI­II, an­gling for a spot in the Covid-19 an­ti­body race led by Lil­ly, Re­gen­eron

5 years ago
R&D
Coronavirus

Io­vance shares ham­mered on TIL ther­a­py fil­ing de­lay — al­though an­a­lysts aren't as both­ered

5 years ago
Cell/Gene Tx

Af­ter weath­er­ing fail­ure, re­jec­tion and lay­offs, Im­muno­Gen touts a new 'break­through' drug in its come­back plan

5 years ago
R&D
FDA+

Op­di­vo/Yer­voy com­bo flops again in melanoma, but Bris­tol My­ers Squibb al­so has a new OK to cel­e­brate

5 years ago
R&D
Pharma

Bris­tol My­ers of­fers a big pre­mi­um to reel in MyoKar­dia's car­dio pipeline with a $13B buy­out

5 years ago
Deals

Covid-19 roundup: EMA starts rolling re­view of As­traZeneca vac­cine; No­vavax ex­ecs sell mil­lions in stock ahead of ...

5 years ago
Coronavirus

Its sale to Al­ler­gan was called off at the last minute. One year lat­er, a biotech co-found­ed by Hen­ri Ter­meer finds a ...

5 years ago
Deals

Gen­fit prunes near­ly half its work­force af­ter NASH ex­it — but CEO promis­es a fu­ture in PBC, di­ag­nos­tics

5 years ago
R&D
First page Previous page 64656667686970 Next page Last page
A service from the Financial Times